CADTH | Evidence Driven
CADTH | Evidence Driven

Efficacy and Safety of Long-Term Use of Omalizumab for the Treatment of Chronic Idiopathic Urticaria

Details

Files
Project Status:
Active
Project Line:
Health Technology Review
Project Sub Line:
Systematic Review
Project Number:
RE0043-000

The objective of this systematic review is to determine the efficacy, effectiveness, and safety of omalizumab administered for 24 weeks or longer in patients with chronic idiopathic urticaria (CIU). The review will also identify the characteristics of patients who use omalizumab for longer than 24 weeks.

In the real-world setting, omalizumab is seeing continued, longer-term use. The evidence will help inform the appropriateness of using long-term omalizumab in patients with CIU.

A companion study (The incidence and prevalence of the long-term use of omalizumab for chronic idiopathic urticaria.) will determine the incidence and prevalence of the long-term use of omalizumab in patients with CIU.  
 

Files

Project Protocol View PDF
Draft Report View PDF
Last Updated : April 19, 2024